Cargando…

Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review

SIMPLE SUMMARY: Approaches beyond first-line chemotherapy to treat advanced cervical cancer (CC) are currently limited. Immune checkpoint inhibitors (ICIs) are showing high efficacy, thus remodeling the therapeutic scenario of many solid tumors. With our systematic review, we aimed to summarize the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maiorano, Brigida Anna, Maiorano, Mauro Francesco Pio, Ciardiello, Davide, Maglione, Annamaria, Orditura, Michele, Lorusso, Domenica, Maiello, Evaristo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737392/ https://www.ncbi.nlm.nih.gov/pubmed/36497437 http://dx.doi.org/10.3390/cancers14235955

Ejemplares similares

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
por: Maiorano, Brigida Anna, et al.
Publicado: (2021)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience
por: Parente, Paola, et al.
Publicado: (2022)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
por: Maiorano, Brigida Anna, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
por: Ciardiello, Davide, et al.
Publicado: (2022)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era
por: Ciardiello, D., et al.
Publicado: (2022)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
por: Tan, Wei Phin, et al.
Publicado: (2019)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
por: Silvestris, Nicola, et al.
Publicado: (2014)

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
por: Ciardiello, Davide, et al.
Publicado: (2023)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Enceladus and the icy moons of Saturn
por: Schenk, Paul M, et al.
Publicado: (2018)

Ici, priorité ... aux piétons !
Publicado: (2002)

L'espion d'ici
por: Omnes, Roland
Publicado: (2000)

Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis
por: He, Yan, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
por: Diana, Anna, et al.
Publicado: (2021)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

ICIS workshop on adnexal mass characterization
por: Rockall, Andrea
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gpcatbr8fqcpevuan67u98e24d